A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

NCT00553813 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient funding

Conditions

Pancreatic Cancer

Interventions

DRUG: TPI 287

Sponsor

Cortice Biosciences, Inc.